FAB — Fusion Antibodies Share Price
Last trade - 00:00- £15.06m
- £14.65m
- £1.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.22 | ||
| Price to Tang. Book | 14.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -152.85% | ||
| Return on Equity | -129.49% | ||
| Operating Margin | -92.29% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 3.9 | 4.17 | 4.8 | 2.9 | 1.14 | 1.96 | 2.25 | -12.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The Company offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development. It offers a range of services including antibody discovery/generation, development, characterization, optimization, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanization using Fusion's proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for downstream use by the customer to produce material for clinical trials. Its Integrated Therapeutic Antibody Services (ITA) offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Directors
- Simon Douglas NEC (63)
- Richard Jones CEO (49)
- James Fair CFO (55)
- Richard Buick CTO (44)
- Alan Mawson NED (79)
- Colin Walsh NED (65)
- Sonya Ferguson NID (50)
- Tim Watts NID (64)
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- November 29th, 2000
- Public Since
- December 18th, 2017
- No. of Employees
- 31
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 113,656,253
- Address
- Springbank Industrial Estate, BELFAST, BT17 0QL
- Web
- https://fusionantibodies.com/
- Phone
- +44 2890432800
- Auditors
- Kreston Reeves LLP
Latest News for FAB
Upcoming Events for FAB
Full Year 2025 Fusion Antibodies PLC Earnings Release
Half Year 2026 Fusion Antibodies PLC Earnings Release
Similar to FAB
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 20:44 UTC, shares in Fusion Antibodies are trading at 13.25p. This share price information is delayed by 15 minutes.
Shares in Fusion Antibodies last closed at 13.25p and the price had moved by +295.52% over the past 365 days. In terms of relative price strength the Fusion Antibodies share price has outperformed the FTSE All Share Index by +256.97% over the past year.
There is no consensus recommendation for this security.
Find out moreFusion Antibodies does not currently pay a dividend.
Fusion Antibodies does not currently pay a dividend.
Fusion Antibodies does not currently pay a dividend.
To buy shares in Fusion Antibodies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 13.25p, shares in Fusion Antibodies had a market capitalisation of £15.06m.
Here are the trading details for Fusion Antibodies:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: FAB
Based on an overall assessment of its quality, value and momentum Fusion Antibodies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fusion Antibodies. Over the past six months, its share price has outperformed the FTSE All Share Index by +52.86%.
As of the last closing price of 13.25p, shares in Fusion Antibodies were trading +77.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Fusion Antibodies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 13.25p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Fusion Antibodies' management team is headed by:
- Simon Douglas - NEC
- Richard Jones - CEO
- James Fair - CFO
- Richard Buick - CTO
- Alan Mawson - NED
- Colin Walsh - NED
- Sonya Ferguson - NID
- Tim Watts - NID